home / stock / crvs / crvs news


CRVS News and Press, Corvus Pharmaceuticals Inc. From 11/09/20

Stock Information

Company Name: Corvus Pharmaceuticals Inc.
Stock Symbol: CRVS
Market: NASDAQ
Website: corvuspharma.com

Menu

CRVS CRVS Quote CRVS Short CRVS News CRVS Articles CRVS Message Board
Get CRVS Alerts

News, Short Squeeze, Breakout and More Instantly...

CRVS - Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Data to be presented in a poster and an oral session “ Hot Topic Symposium : COVID-19 and Cancer ” at SITC Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2 Plan...

CRVS - Seeking Alpha Catalyst Watch

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

CRVS - Corvus Pharmaceuticals COVID-19 Abstract Selected for "Hot Topic" Oral Session at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

BURLINGAME, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its abstract covering updated data from its Phase 1 study investigating the potential for CPI-006 to provide a novel immunother...

CRVS - Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results

BURLINGAME, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the third quarter ended September 30, 2020. “We have several impor...

CRVS - Corvus Pharmaceuticals to Present Updated Data from its Clinical Trial of CPI-006 for Patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

BURLINGAME, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present updated data from its Phase 1 study investigating the potential for CPI-006 to provide a novel immunothera...

CRVS - Week In Review: $1.5 Billion Total In Week's China Deals

10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million. Corvus Pharma formed a China subsidiary, Angel Pharma, to develop its three clinical-stage assets and one preclinical platform in China. Zai Lab of Shanghai has dosed the first patient in...

CRVS - WWR, MYOK, EPR and FCEL among midday movers

Gainers: Greenpro Capital (GRNQ) +85%.MyoKardia (MYOK) +58%.Westwater Resources (WWR) +53%.Eidos Therapeutics (EIDX) +40%.Scully Royalty (SRL) +34%.Enlivex Therapeutics (ENLV) +28%.Humanigen (HGEN) +24%.Corvus Pharmaceuticals (CRVS) +22%.Piedmont Lithium (PLL) +22%.Pulse Biosciences (PLS...

CRVS - MyoKardia, Eidos Therapeutics leads healthcare gainers, Xtant Medical Holdings, Curis among major losers

Gainers: MyoKardia (MYOK) +58%, Eidos Therapeutics (EIDX) +41%, Enlivex Therapeutics (ENLV) +25%, Humanigen (HGEN) +28%, Corvus Pharmaceuticals (CRVS) +26%.Losers: Xtant Medical Holdings (XTNT) -15%, Curis (CRIS) -7%, Immunome (...

CRVS - What Are The Best Penny Stocks To Buy Now? 5 Moving Premarket

Are These Pre Market Penny Stocks On Your Watch List? Are you looking for the best penny stocks to buy now? I’m sure you and hundreds of other traders are scouring through stock charts and looking at scanners to pick up on the next big momentum move in the stock market to...

CRVS - MYOK, TEF among premarket gainers

MyoKardia (MYOK) +59% as Bristol to acquire the company for $225/Share.Kosmos Energy (KOS) +50% as company closed a Gulf of Mexico facility with Beal Bank USA and Trafigura Trading LLC.Enlivex Therapeutics (ENLV) +49%.Corvus Pharmaceuticals (CRVS) +38% on co-foun...

Previous 10 Next 10